By Isnaini Azizah 
The Food and Drug Administration on Thursday approved a higher-dose version of Novo Nordisk’s blockbuster weight loss injection Wegovy, marking a pivotal moment in the escalating pharmaceutical arms race between the Danish drugmaker and its primary American rival, Eli Lilly. The approval of the 7.2-milligram dose of semaglutide—the active ingredient in Wegovy—is designed to provide patients and healthcare providers with a more potent tool to combat chronic obesity, a condition that affects nearly 42% of the adult population in the United States. Novo Nordisk expects to launch this high-dose variant in April, positioning it as a direct counter-offensive to Eli Lilly’s Zepbound, which has rapidly seized market share since its introduction.
The strategic necessity of this approval cannot be overstated for Novo Nordisk. While Wegovy was the first-to-market GLP-1 (glucagon-like peptide-1) receptor agonist specifically indicated for chronic weight management, it has recently faced stiff competition from Eli Lilly’s tirzepatide, marketed as Zepbound for obesity and Mounjaro for type 2 diabetes. Clinical data has consistently suggested that Zepbound, which targets both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, offers superior weight loss outcomes compared to the standard 2.4-milligram dose of Wegovy. By increasing the dosage of semaglutide to 7.2 milligrams, Novo Nordisk aims to bridge this efficacy gap and offer a treatment profile that rivals the top-tier performance of its competitor.
In the phase three clinical trials that paved the way for this FDA decision, the 7.2-milligram dose of Wegovy demonstrated impressive results. Patients without diabetes who received the higher dose achieved an average weight loss of 20.7% over a 72-week period. This represents a significant leap from the 15% average weight loss typically observed with the standard 2.4-milligram dose in earlier trials. For the millions of Americans struggling with obesity, this extra 5% to 6% of body weight reduction can mean the difference between clinical improvement and the resolution of comorbid conditions such as sleep apnea, hypertension, and joint pain.
Dr. Jason Brett, the principal U.S. medical head at Novo Nordisk, emphasized the clinical importance of this "efficacy delta" in an interview preceding the approval. "I think it really makes it more competitive, and it really reduces the delta there," Dr. Brett noted. He further explained that the higher dose is not just about competing with Eli Lilly, but about providing a secondary tier of treatment for patients who may have hit a plateau on the standard dose. "Even more importantly, I think it just gives patients another option if they’re not reaching their targets, and achieving some of these higher weight losses for certain patients," he added.
The approval also brings good news for the type 2 diabetes community. In a separate phase three trial specifically targeting patients with both obesity and type 2 diabetes, the 7.2-milligram Wegovy dose resulted in an average weight loss of 14.1%. While this figure is lower than the results seen in patients without diabetes, it is a notable achievement given the metabolic complexities of the disease. Historically, patients with type 2 diabetes find it significantly harder to lose weight due to insulin resistance and the metabolic effects of various glucose-lowering medications. Providing a higher-potency option allows this demographic to achieve weight loss milestones that were previously considered unattainable through pharmacological intervention alone.
The regulatory path for the 7.2-milligram dose was notably accelerated, marking the first time a GLP-1 treatment has been approved under the FDA’s new national priority voucher plan. This pilot program, launched in June, was designed to incentivize pharmaceutical companies to address what the agency deems "national health priorities." By utilizing this voucher, Novo Nordisk was able to shorten the review period to just one to two months, a process that typically takes six months to a year. The inclusion of obesity drugs in this priority program underscores the federal government’s growing recognition of obesity as a public health crisis with massive economic and social implications.
The backdrop of this approval is a market that analysts predict could be worth over $100 billion by the end of the decade. Eli Lilly and Novo Nordisk currently exist in a duopoly, struggling to keep up with an insatiable global demand for these "miracle" weight loss drugs. Eli Lilly’s Zepbound has recently been hailed as the "gold standard" for weight loss because of its dual-agonist mechanism. However, Novo Nordisk’s move to a 7.2-milligram dose of semaglutide suggests that the potency of a single-agonist drug can be pushed further than previously thought. This "dose escalation" strategy allows Novo Nordisk to maximize the potential of its existing semaglutide molecule while it continues to develop next-generation compounds like cagrisema.
The competitive landscape is further complicated by issues of supply and accessibility. Both companies have invested billions of dollars into expanding their manufacturing capabilities. Novo Nordisk’s parent company recently moved to acquire Catalent, a major drug manufacturer, to bolster its filling and finishing capacity for the Wegovy pens. Eli Lilly has similarly broken ground on massive new facilities in Indiana and Germany. The introduction of a 7.2-milligram dose adds a new layer to these logistics, as the company must now manage the production and distribution of an additional SKU (stock-keeping unit) in an environment where the standard doses are still frequently on the FDA’s drug shortage list.
From a clinical perspective, the higher dose will require careful management by healthcare providers. GLP-1 medications are known for gastrointestinal side effects, including nausea, vomiting, and diarrhea, which are usually dose-dependent. The titration process—whereby a patient gradually increases their dose over several months—will be even more critical with a 7.2-milligram ceiling. Doctors will need to balance the desire for maximum weight loss with the patient’s ability to tolerate the medication. However, Novo Nordisk has indicated that the safety profile of the 7.2-milligram dose remains consistent with the 2.4-milligram dose, with no new or unexpected safety signals emerging during the phase three trials.
The economic implications for insurers and employers are also significant. As the efficacy of these drugs increases, so does the pressure on insurance providers to cover them. Currently, many Medicare and private insurance plans remain hesitant to cover weight loss medications due to their high monthly costs, which can exceed $1,000 without discounts. However, as Novo Nordisk and Eli Lilly provide more data showing that higher doses lead to better long-term health outcomes—such as reduced cardiovascular events—the argument for broad coverage becomes more compelling. Novo Nordisk’s previous SELECT trial already demonstrated that Wegovy can reduce the risk of major adverse cardiovascular events by 20%, and the higher dose may potentially amplify these protective effects.
As the April launch approaches, the pharmaceutical industry will be watching closely to see how prescribers react. Will they immediately move patients who have plateaued on 2.4 milligrams to the 7.2-milligram dose? And how will Eli Lilly respond? Industry insiders expect Lilly to continue emphasizing the "dual-action" benefit of tirzepatide while perhaps exploring its own higher-dose formulations or triple-agonist candidates like retatrutide, which is currently in late-stage development and has shown even more dramatic weight loss in early trials.
The FDA’s approval of the 7.2-milligram Wegovy dose represents more than just a regulatory win; it is a tactical maneuver in a global health shift. Obesity is no longer viewed merely as a lifestyle issue but as a chronic biological disease that requires long-term, high-potency medical management. By pushing the boundaries of what semaglutide can achieve, Novo Nordisk is attempting to reclaim its crown and ensure that it remains an indispensable partner in the journey toward metabolic health for millions of people worldwide. The "delta" may be narrowing, but the race to solve the obesity epidemic is only just beginning.